Development of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting
Source abstract
Abstract
The natural flavonoid fisetin (FS) has shown anticancer properties but its in-vivo administration remains challenging due to its poor aqueous solubility. The aim of the study was to develop FS loaded pluronic127 (PF)-folic acid (FA) conjugated micelles (FS-PF-FA) by the way of increasing solubility, bioavailability and active targetability of FS shall increase its therapeutic efficacy. FA-conjugated PF was prepared by carbodiimide crosslinker chemistry. FS-PF-FA micelles were prepared by thin-film hydration method and evaluated in comparison with free FS and FS loaded PF micelles (FS-PF). The smooth surfaces with spherical in shape of FS-PF-PF micelles displayed smaller in size (103.2 ± 6.1 nm), good encapsulation efficiency (82.50 ± 1.78%), zeta potential (-26.7 ± 0.44 mV) and sustained FS release. Bioavailability of FS from FS-PF-PF micelles was increased by 6-fold with long circulation time, slower plasma elimination and no sign of tissue toxicity as compared to free FS. Further, the FS-PF-FA micelles demonstrated active targeting effect on folate overexpressed human breast cancer MCF-7 cells. The concentration of the drug needed for growth inhibition of 50% of cells in a designed time period (GI50) was 14.3 ± 1.2 µg/ml for FS while it was greatly decreased to 9.8 ± 0.78 µg/ml, i.e. a 31.46% decrease for the FS-PF. Furthermore, the GI50 value for FS-PF-FA was 4.9 ± 0.4 µg/ml, i.e. a 65.737% decrease compared to FS and 50% decrease compare to FS-PF. The results indicate that the FS-PF-FA micelles have the potential to be applied for targeting anticancer drug delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Flavonoids in Medical Research · Natural Compounds in Disease Treatment · Clusterin in disease pathology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University
Department of Pharmaceutics, Dr. D. Y. Patil College of Pharmacy
Department of Pharmaceutics, Modern College of Pharmacy
References (49)
Show source-provided references
1. 10.1080/21691401.2017.136633310.1080/21691401.2017.1366333 ↗
2. 10.1093/jn/130.9.224310.1093/jn/130.9.2243 ↗
3. 10.1016/j.fct.2011.12.01510.1016/j.fct.2011.12.015 ↗
4. 10.1016/j.foodchem.2013.01.06010.1016/j.foodchem.2013.01.060 ↗
5. 10.1016/j.fct.2010.05.05810.1016/j.fct.2010.05.058 ↗
6. 10.1016/j.bionut.2012.04.00510.1016/j.bionut.2012.04.005 ↗
7. 10.1007/s00280-010-1505-810.1007/s00280-010-1505-8 ↗
8. 10.1158/1535-7163.MCT-10-060610.1158/1535-7163.MCT-10-0606 ↗
9. 10.1016/j.canlet.2010.09.01510.1016/j.canlet.2010.09.015 ↗
10. 10.1016/j.bcp.2012.07.01210.1016/j.bcp.2012.07.012 ↗
11. Chen Y, Wu Q, Song L, et al. Polymeric micelles encapsulating fisetin improve therapeutic effect in colon cancer. ACS Appl Mater Interfaces. 2014;14:534–542.
12. 10.1007/s11010-009-0217-z10.1007/s11010-009-0217-z ↗
13. 10.1158/0008-5472.CAN-08-024010.1158/0008-5472.CAN-08-0240 ↗
14. 10.1016/j.ijpharm.2011.04.06610.1016/j.ijpharm.2011.04.066 ↗
15. 10.1016/j.bcp.2011.07.09710.1016/j.bcp.2011.07.097 ↗
16. 10.1016/j.ijpharm.2013.01.05010.1016/j.ijpharm.2013.01.050 ↗
17. 10.1016/j.ijpharm.2012.02.02510.1016/j.ijpharm.2012.02.025 ↗
18. 10.1016/j.ejpb.2013.02.01610.1016/j.ejpb.2013.02.016 ↗
19. 10.1016/S0001-8686(03)00115-510.1016/S0001-8686(03)00115-5 ↗
20. 10.1517/17425247.2013.86013110.1517/17425247.2013.860131 ↗
21. 10.1039/C6RA12714B10.1039/C6RA12714B ↗
22. 10.1039/C6RA24595A10.1039/C6RA24595A ↗
23. 10.1080/21691401.2017.139487210.1080/21691401.2017.1394872 ↗
24. 10.1080/21691401.2017.136633810.1080/21691401.2017.1366338 ↗
25. 10.1080/21691401.2017.133702910.1080/21691401.2017.1337029 ↗
26. 10.1016/j.jconrel.2011.06.00110.1016/j.jconrel.2011.06.001 ↗
27. 10.1021/bm501558d10.1021/bm501558d ↗
28. 10.2147/IJN.S2874510.2147/IJN.S28745 ↗
29. 10.4155/tde.13.9210.4155/tde.13.92 ↗
30. 10.1166/nnl.2009.102910.1166/nnl.2009.1029 ↗
31. 10.1007/s13318-010-0016-710.1007/s13318-010-0016-7 ↗
32. 10.1504/IJNT.2011.04144410.1504/IJNT.2011.041444 ↗
33. 10.1179/1753555714Y.000000017410.1179/1753555714Y.0000000174 ↗
34. 10.1038/nrc118910.1038/nrc1189 ↗
35. 10.1039/c0cc00855a10.1039/c0cc00855a ↗
36. 10.1016/j.biomaterials.2009.06.00410.1016/j.biomaterials.2009.06.004 ↗
37. 10.2147/IJN.S7843810.2147/IJN.S78438 ↗
38. 10.1039/c3ra46209a10.1039/c3ra46209a ↗
39. Varshosaz J, Hassanzadeh F, Sadeghi Aliabadi H, et al. Synthesis and characterization of folate-targeted dextran/retinoic acid micelles for doxorubicin delivery in acute leukemia. Bio Med Res Int. 2014;2:1–14.
40. 10.3109/1061186X.2014.91305210.3109/1061186X.2014.913052 ↗
41. 10.1080/09205063.2015.103013610.1080/09205063.2015.1030136 ↗
42. 10.1085/jgp.78.4.34910.1085/jgp.78.4.349 ↗
43. 10.1021/am505531e10.1021/am505531e ↗
44. 10.1080/21691401.2017.137667510.1080/21691401.2017.1376675 ↗
45. 10.1016/S0169-409X(00)00121-610.1016/S0169-409X(00)00121-6 ↗
46. 10.1016/j.jss.2008.06.04910.1016/j.jss.2008.06.049 ↗
47. 10.2217/nnm.11.11110.2217/nnm.11.111 ↗
48. 10.1080/21691401.2017.136633710.1080/21691401.2017.1366337 ↗
49. 10.1080/21691401.2017.140812310.1080/21691401.2017.1408123 ↗